In vivo effects of dexmedetomidine on immune function and tumor growth in rats with ovarian cancer through inhibiting the p38MAPK/NF-κB signaling pathway
Author:
Publisher
Elsevier BV
Subject
Pharmacology,General Medicine
Reference23 articles.
1. Bevacizumab in ovarian cancer: a critical review of phase III studies;Rossi;Oncotarget,2017
2. Molecular and clinical implementations of ovarian cancer mouse avatar models;Zayed;Chin. Clin. Oncol.,2015
3. Neferine induces autophagy of human ovarian cancer cells via p38 MAPK/JNK activation;Xu;Tumour Biol.,2016
4. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review;Aravantinos;J. Ovarian Res.,2014
5. The PI3 K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges;Cheaib;Chin. J. Cancer,2015
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Retraction notice to “In vivo effects of dexmedetomidine on immune function and tumor growth in rats with ovarian cancer through inhibiting the p38MAPK/NF-κB signaling pathway” [Biomed. Pharmacother. 95 (2017) 1830–1837];Biomedicine & Pharmacotherapy;2023-12
2. TNFAIP3 interacting protein 2 relieves lipopolysaccharide (LPS)‐induced inflammatory injury in endometritis by inhibiting NF‐kappaB activation;Immunity, Inflammation and Disease;2023-10
3. Dexmedetomidine promotes autophagy and apoptosis of colon cancer cells by activating endoplasmic reticulum (ER) stress-mediated PERK/eIF2α/ATF4 signaling pathway;Molecular & Cellular Toxicology;2023-06-02
4. Effect of intraoperative dexmedetomidine on long-term survival in older patients after major noncardiac surgery: 3-year follow-up of a randomized trial;Journal of Clinical Anesthesia;2023-06
5. Curcumol, a major terpenoid from Curcumae Rhizoma, attenuates human uterine leiomyoma cell development via the p38MAPK/NF-κB pathway;Journal of Ethnopharmacology;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3